Vical (NASDAQ:VICL) vs. Outlook Therapeutics (NASDAQ:OTLK) Critical Survey

Vical (NASDAQ:VICL) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.

Insider & Institutional Ownership

33.8% of Vical shares are held by institutional investors. Comparatively, 0.8% of Outlook Therapeutics shares are held by institutional investors. 4.6% of Vical shares are held by insiders. Comparatively, 11.5% of Outlook Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Vical and Outlook Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vical -1,002.10% -32.59% -30.61%
Outlook Therapeutics -1,250.20% N/A -143.81%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Vical and Outlook Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vical 0 2 0 0 2.00
Outlook Therapeutics 0 0 3 0 3.00

Vical currently has a consensus target price of $4.00, indicating a potential upside of 426.18%. Outlook Therapeutics has a consensus target price of $9.33, indicating a potential upside of 342.34%. Given Vical’s higher possible upside, research analysts clearly believe Vical is more favorable than Outlook Therapeutics.

Risk & Volatility

Vical has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of -0.86, suggesting that its share price is 186% less volatile than the S&P 500.

Valuation and Earnings

This table compares Vical and Outlook Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vical $1.62 million 10.71 -$16.25 million ($0.81) -0.94
Outlook Therapeutics $3.09 million 17.79 -$30.09 million ($10.80) -0.20

Vical has higher earnings, but lower revenue than Outlook Therapeutics. Vical is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Vical Company Profile

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.

Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.